ReportWire

Tag: Healthcare/Life Sciences

  • China Approves Merck’s Molnupiravir for Emergency Use, Regulator Says

    China Approves Merck’s Molnupiravir for Emergency Use, Regulator Says

    [ad_1]

    China’s top drug regulator said Friday that it approved Merck & Co.’s Molnupiravir for emergency use on Thursday, as the country grapples with waves of infections after Beijing abruptly reversed its stringent Covid-19 restrictions earlier this month.

    The National Medical Products Administration said it is requiring the approval holder to continue relevant research, complete conditional requirements and submit follow-up research results in a timely manner, according to a statement posted on its website Friday.

    Write to Singapore Editors at singaporeeditors@dowjones.com

    Corrections & Amplifications

    This item was corrected at 0856 GMT to reflect China’s top drug regulator said it approved Merck & Co.’s Molnupiravir for emergency use on Thursday. The original version incorrectly said the approval came on Wednesday in the first paragraph.

    [ad_2]

    Source link

  • Novozymes and Chr. Hansen agree deal to merge

    Novozymes and Chr. Hansen agree deal to merge

    [ad_1]

    Danish biotechnology companies Novozymes AS
    NZYM.B,
    -10.74%

    and Chr. Hansen Holding AS
    CHR,
    +25.98%

    said Monday they have agreed to merge, creating a biological solutions provider with combined annual revenue of around 3.5 billion euros ($3.69 billion).

    The companies, which produce products such as enzymes, probiotics and biopharmaceutical ingredients, said the combination between two strategically complementary businesses will drive efficiencies while unlocking potential within biosolutions and providing additional growth opportunities.

    “Novozymes and Chr. Hansen share the strong conviction that our combined scale, know-how, commercial strengths, and innovation excellence will drive value for our shareholders, customers and society at large,” said Novozymes Chief Executive Ester Baiget.

    The deal will see Chr. Hansen shareholders receive 1.5326 new B-shares in Novozymes for each Chr. Hansen share, reflecting an implied premium of 49% to Chr. Hansen’s closing share price on Friday and valuing each Chr. Hansen share at 660.55 Danish kroner ($93.53) a share.

    Novo Holdings AS, the largest shareholder in both Novozymes and Chr. Hansen, will support the proposed merger and exchange its 22% stake in Chr. Hansen at an exchange ratio of 1.0227 new B-shares in Novozymes.

    The companies said they see annual revenue synergies of EUR200 million within four years after completion of the deal.

    Write to Dominic Chopping at dominic.chopping@wsj.com

    [ad_2]

    Source link

  • WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon Therapeutics

    WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon Therapeutics

    [ad_1]

    U.S. biotechnology company was the last of three suitors standing in an auction for Horizon

    [ad_2]
    Source link

  • This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.

    This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.

    [ad_1]

    What worked well during the years-long bull market through 2021 — a focus on growth, regardless of price — has ground to a halt this year. The rebirth of the value style of investing — and modest valuations overall — has taken hold.

    The approach taken by the Invesco S&P 500 GARP ETF has paid off through both bull and bear markets.

    Let’s begin with a 10-year chart comparing total returns with dividends reinvested for the Invesco S&P 500 GARP ETF
    SPGP,
    +0.67%

    and the SPDR S&P 500 ETF Trust
    SPY,
    +0.78%
    ,
    which tracks the benchmark S&P 500:


    FactSet

    So far this year, SPGP is down 12%, while SPY is down 16%. But the long-term chart shows significant and consistent outperformance for SPGP, even during the bull market.

    The S&P 500 GARP Index

    GARP stands for “growth at a reasonable price.” SPGP tracks the S&P 500 GARP Index, which is reconstituted and rebalanced twice a year, on the third Fridays of June and December. The next change occurs Dec. 16.

    S&P Dow Jones Indices assigns a growth score to each component of the S&P 500 by averaging the three-year compound annual growth rate (CAGR) for earnings and sales per share.

    The top 150 components of the S&P 500 by growth score are eligible for inclusion in the GARP index. Those 150 are ranked by “quality/value composite score,” which is the average of these three ratios:

    • Financial leverage — total debt to book value.

    • Return on equity — trailing 12 months’ earnings per share divided by book value per share.

    • Earnings-to-price — 12 months’ earnings per share divided by the share price.

    The top 75 of the 150 by QV rankings are then included in the GARP index and weighted by the growth score, with portfolio weightings ranging from 0.5% to 5%.

    There is a weighting limitation of 40% to any one of the 11 S&P sectors.

    Addressing concentration risk

    The benchmark S&P 500 Index
    SPX,
    +0.75%

    is weighted by market capitalization, which means it is more heavily concentrated than you might expect — success is rewarded, with rising stocks more heavily weighted over time.

    That can backfire during a bear market, with Amazon.com Inc.
    AMZN,
    +2.14%

    down 47% and Tesla Inc.
    TSLA,
    -0.34%

    down 51% this year, to name two prominent examples.

    Looking at the SPDR S&P 500 ETF Trust
    SPY,
    +0.78%
    ,
    which is the first and largest exchange traded fund and tracks the benchmark index by holding all of its components, six companies (Apple Inc.
    AAPL,
    +1.21%
    ,
    Microsoft Corp.
    MSFT,
    +1.24%
    ,
    Amazon, both common share classes of Alphabet Inc.
    GOOGL,
    -1.30%

     
    GOOG,
    -1.26%

    and Berkshire Hathaway Inc.
    BRK.B,
    +0.06%

    ) make up 19.2% of the portfolio.

    That percentage has come down this year, but a lot of risk remains concentrated in a handful of companies. (Apple alone makes up 6.4% of the SPY portfolio. Tesla is now the ninth-largest holding, making up 1.4% of the portfolio.)

    One way to address high concentration in an index fund is to use an equal-weighted approach, which Mark Hulbert recently discussed.

    For the Invesco S&P 500 GARP ETF, the underlying index’s selection methodology has resulted in much less portfolio concentration than we see in SPY, with the top five holdings making up 10.9% of the portfolio.

    Here are the 10 largest holdings of SPGP:

    Company

    Ticker

    Share of portfolio

    Regeneron Pharmaceuticals, Inc.

    REGN,
    +0.15%
    2.49%

    Cigna Corporation

    CI,
    +0.39%
    2.26%

    Everest Re Group, Ltd.

    RE,
    +0.24%
    2.21%

    Vertex Pharmaceuticals Incorporated

    VRTX,
    +1.18%
    1.98%

    D.R. Horton, Inc.

    DHI,
    -0.39%
    1.97%

    Expeditors International of Washington, Inc.

    EXPD,
    +0.23%
    1.96%

    Incyte Corporation

    INCY,
    +0.10%
    1.92%

    Goldman Sachs Group, Inc.

    GS,
    -0.51%
    1.83%

    Ebay Inc.

    EBAY,
    +1.67%
    1.81%

    Pfizer Inc.

    PFE,
    +3.07%
    1.73%

    Source: FactSet

    Click on the tickers for more information about any company, ETF or index in this article.

    You should also read Tomi Kilgore’s detailed guide to the wealth of information for free on the MarketWatch quote page.

    Don’t miss: 10 Dividend Aristocrat stocks expected by analysts to rise up to 54% in 2023

    [ad_2]

    Source link

  • Ex-Theranos exec ‘Sunny’ Balwani sentenced to nearly 13 years in prison

    Ex-Theranos exec ‘Sunny’ Balwani sentenced to nearly 13 years in prison

    [ad_1]

    SAN JOSE, Calif. — A judge on Wednesday sentenced former Theranos executive Ramesh “Sunny” Balwani to nearly 13 years in prison for his role in the company’s blood-testing hoax — a sentence slightly longer than that given to the CEO, who was his lover and accomplice in one of Silicon Valley’s biggest scandals.

    Balwani was convicted in July of fraud and conspiracy connected to the company’s bogus medical technology that duped investors and endangered patients. His sentencing came less than three weeks after Elizabeth Holmes, the company’s founder and CEO, received more than 11 years in prison for her part in the scheme.

    The scandal revolved around the company’s false claims to have developed a device that could scan for hundreds of diseases and other potential problems with just a few drops of blood taken with a finger prick.

    The case threw a bright light on Silicon Valley’s dark side, exposing how its culture of hype and boundless ambition could veer into lies.

    Holmes, 38, could have gotten up to 20 years in prison — a penalty that U.S. District Judge Edward Davila could have imposed on Balwani, who spent six years as Theranos’ chief operating officer while remaining romantically involved with Holmes until a bitter split in 2016.

    While on the witness stand in her trial, Holmes accused Balwani, 57, of manipulating her through years of emotional and sexual abuse. Balwani’s attorney has denied the allegations.

    The two trials had somewhat different outcomes. Unlike Balwani, Holmes was acquitted on several charges of defrauding and conspiring against people who paid for Theranos blood tests that produced misleading results and could have pointed patients toward the wrong treatment. The jury in Holmes’ trial also deadlocked on three charges.

    Balwani was convicted on all 12 felony counts, and his lawyers sought a far more lenient sentence of just four to 10 months in prison. Prosecutors for the Justice Department asked for 15 years. A probation report recommended nine years.

    Duncan Levin, a former federal prosecutor who is now a defense attorney, described Balwani’s bid for a light sentence as “utterly unrealistic.” Levin suspects the judge may give greater weight to the Justice Department and the probation office recommendations, which mirror the sentences those agencies sought for Holmes.

    The judge ultimately gave her 11 1/4 years in prison and recommended that the sentence be served in a low-security facility in Byran, Texas.

    Federal prosecutors also want the judge to order Balwani to pay $804 million in restitution to defrauded investors — the same amount sought from Holmes. Davila deferred a decision on restitution during Holmes’ Nov. 18 sentencing until an unspecified future date.

    In court documents, Balwani’s lawyers painted him as a hardworking immigrant who moved from India to the U.S. during the 1980s to become the first member of his family to attend college. He graduated from the University of Texas in 1990 with a degree in information systems.

    He later moved to Silicon Valley, where he first worked as a computer programmer for Microsoft before founding an online startup that he sold for millions of dollars during the dot-com boom of the 1990s.

    Balwani and Holmes met around the same time she dropped out of Stanford University to start Theranos in 2003. He became enthralled with her and her quest to revolutionize health care.

    Balwani’s lawyers said he eventually invested about $5 million in a stake in Theranos that eventually became worth about $500 million on paper — a fraction of Holmes’ one-time fortune of of $4.5 billion.

    That wealth evaporated after Theranos began to unravel in 2015 amid revelations that its blood-testing technology never worked as Holmes had boasted in glowing magazine articles that likened her to Silicon Valley visionaries such as Apple co-founder Steve Jobs.

    Before Theranos’ downfall, Holmes teamed up with Balwani to raise nearly $1 billion from deep-pocketed investors that included software mogul Larry Ellison and media magnate Rupert Murdoch.

    “Mr. Balwani is not the same as Elizabeth Holmes,” his lawyers wrote in a memo to the judge. “”He actually invested millions of dollars of his own money; he never sought fame or recognition; and he has a long history of quietly giving to those less fortunate.” Balwani’s lawyers also asserted that Holmes “was dramatically more culpable” for the Theranos fraud.

    Echoing similar claims made by Holmes’s lawyers before her sentencing, Balwani’s attorneys also argued that he has been adequately punished by the intense media coverage of Theranos, which has been the subject of a book, documentary and award-winning TV series.

    Balwani “has lost his career, his reputation and his ability to meaningfully work again,” his lawyers wrote.

    Federal prosecutors cast Balwani as a ruthless, power-hungry accomplice in crimes that ripped off investors and imperiled people who received flawed results. The blood tests were to be available in a partnership with Walgreen’s that Balwani helped engineer.

    “Balwani presented a fake story about Theranos’ technology and financial stability day after day in meeting after meeting,” the prosecutors wrote in their memo to the judge. “Balwani maintained this façade of accomplishments, after making the calculated decision that honesty would destroy Theranos.”

    [ad_2]

    Source link

  • BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI

    BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI

    [ad_1]

    By Colin Kellaher

    Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the potential of its NE3107 drug candidate in Parkinson’s disease and Alzheimer’s disease.

    The Carson City, Nev., company said the study of NE3107 in Parkinson’s met both main objectives, with patients treated with a combination of the drug and levodopa seeing meaningful improvements in their motor score and an absence of adverse interactions of NE3107 with levodopa.

    BioVie said that based on the study findings, it will proceed with planning the Phase 3 program for discussion with the U.S. Food and Drug Administration.

    Meanwhile, BioVie said patients treated with NE3107 in the Alzheimer’s study experienced improved cognition and biomarker levels, with no drug-related adverse events observed.

    BioVie shares, which closed Monday at $5.21, were recently up 15% to $5.98 in premarket trading.

    Write to Colin Kellaher at colin.kellaher@wsj.com

    [ad_2]

    Source link

  • Elizabeth Holmes sentenced to over 11 years in prison for Theranos crimes

    Elizabeth Holmes sentenced to over 11 years in prison for Theranos crimes

    [ad_1]

    Theranos founder and former chief executive Elizabeth Holmes was sentenced to 135 months, or over 11 years, in prison, putting an endpoint on the unraveling of a onetime vigorously hyped Silicon Valley startup that collapsed under allegations of fraud.

    The sentence, handed down from U.S. District Judge Edward Davila, came after Holmes was convicted in January of defrauding investors in the blood-testing company, which purported to have technology that could identify diseases from a pinprick of blood from the tip of a finger.

    Prior to the sentencing, Holmes had sought more lenient treatment, while prosecutors aimed for more. Holmes had requested up to 18 months in prison, along with home confinement and community service, according to The Wall Street Journal. Prosecutors sought 15 years in prison, a three-year supervised release and restitution of $800 million, the Journal said.

    Holmes had until April 27 to surrender, and 14 days to appeal the conviction, according to the Journal. Her lawyers said they would seek permission to keep her out of prison on bail, pending appeal, the Journal said.

    Founded in 2003, Theranos’ value over the years ballooned to $9 billion. But the company’s pitch of simple-to-use blood-testing technology — which attracted the likes of the Walton and Murdoch families, along with former U.S. Secretary of State Henry Kissinger — began to fall apart in 2015, after reporting from the Wall Street Journal raised questions about the claims’ veracity.

    The Securities and Exchange Commission in 2018 charged Holmes and former president Ramesh “Sunny” Balwani with what the agency called “massive fraud,” leading Holmes to give up control of the company. Criminal charges, and the company’s dissolution, followed later that year.

    [ad_2]

    Source link

  • GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint

    GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint

    [ad_1]

    By Michael Susin

    GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free survival.

    The pharmaceutical giant said that the study compared its monotherapy Blenrep versus pomalidomide in combination with low dose dexamethasone and observed median progression-free survival was longer for Blenrep.

    “These trials are designed to demonstrate the benefit of Blenrep in combination treatment with novel therapies and standard-of-care treatments in earlier lines of therapy and dosing optimization to maintain efficacy while reducing corneal events,” it added.

    The company said additional trials will continue and further data from the studies are anticipated in the first half of 2023.

    Write to Michael Susin at michael.susin@wsj.com

    [ad_2]

    Source link

  • Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a day

    Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a day

    [ad_1]

    First the good news: Pfizer Inc. and Germany-based partner BioNTech SE said updated trial data for their omicron BA.4/BA.5-adapted bivalent booster showed a “substantially higher” immune response in adults than the original COVID-19 vaccine.

    The companies said the Phase 2/3 clinical-trial data, collected one month after the boosters were given, also demonstrated that safety and tolerability profiles were similar to those of the original vaccine.

    The news sent Pfizer’s stock
    PFE,
    +0.51%

    rallying 1.7% and BioNTech’s U.S.-listed shares
    BNTX,
    +4.97%

    22UA,
    +4.11%

    surging 7.2% in morning trading.

    “As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible in order to maintain high levels of protection against the widely circulating Omicron BA.4 and BA.5 sublineages,” said Pfizer Chief Executive Albert Bourla.

    Only 8.4% of eligible Americans have received updated COVID booster shots, while 68.5% of the total population have completed the original primary series of vaccinations, according to the latest data from the Centers for Disease Control and Prevention.

    The bivalent booster has been authorized for emergency use in the U.S. by the Food and Drug Administration for people age 5 and older and has also been granted marketing authorization in the European Union for those age 12 and older.

    In another piece of good news, Pfizer and BioNTech shares were also lifted by a report in The Wall Street Journal that the Chinese government has agreed to approve the companies’ COVID-19 vaccines for foreign residents in China and has also held talks to approve those vaccines for the broader population.

    Meanwhile, Bloomberg reported that China was working on a plan to end the practice of penalizing airlines that bring COVID-infected people into the country.

    Both reports boost hopes that China is slowly moving toward ending its zero-COVID policy, which has crimped China’s economy and acted as a drag on global growth.

    Now for the bad news.

    The seven-day average of new COVID cases topped 40,000 for the first time in a month and hospitalizations have also ticked higher, with more than half of U.S. states showing increases over the past two weeks.

    According to a New York Times tracker, the daily average of new cases rose to 40,101 on Thursday from 38,208 on Wednesday, and was up 6% from 14 days ago.


    The New York Times

    Nevada has seen a 96% jump in daily cases, followed by Tennessee with a 69% increase and Louisiana with a 68% rise, leading the 28 states that saw cases increase over the past two weeks.

    Still, daily cases were less than one-third of the summer high of more than 130,000 reached during the surge of the BA.5 variant, the data show.

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    The daily average of COVID-related hospitalizations rose 2% to 27,252, while the number of people with COVID in intensive-care units (ICUs) fell 2% to 3,110.

    The daily average of COVID-related deaths fell 6% to a four-month low of 339.

    On a global basis, the total number of COVID cases has increased to 631.91 million, while deaths have reached 6,598,197, according to data provided by Johns Hopkins University. The U.S. has seen a total of 97.69 million cases and 1,072,245 deaths.

    [ad_2]

    Source link

  • Weekly tally of COVID cases and deaths continues to fall; Moderna lowers vaccine-sales outlook by as much as $3 billion

    Weekly tally of COVID cases and deaths continues to fall; Moderna lowers vaccine-sales outlook by as much as $3 billion

    [ad_1]

    The global tally of COVID-19 cases fell 17% in the week through Oct. 30 from the previous week, while the death toll fell 5%, the World Health Organization said in its weekly update on the virus.

    The omicron variant BA.5 remained dominant globally, accounting for 74.9% of cases sent to a central database. WHO reiterated that newer sublineages of omicron, including BQ.1 and XBB, still appear no more lethal than earlier ones and do not warrant the designation of “variant of concern.”

    But BQ.1 rose in prevalence to 9.0% globally from 5.7% a week ago, while XBB rose to 1.5% from 1.0%.

    “WHO will continue to closely monitor the XBB and BQ.1 lineages as part of omicron and requests countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparative
    analyses of the different omicron sublineages,” the agency wrote.

    WHO has cautioned that changes in testing and reduced surveillance of the virus are making some of the numbers unreliable and has urged leaders to renew efforts to monitor and track developments.

    In the U.S., known cases of COVID remain at their lowest level since mid-April, although the true tally is likely higher given how many people overall are testing at home, where data are not being collected.

    The daily average for new cases stood at 39,090 on Wednesday, according to a New York Times tracker, up 3% versus two weeks ago. The daily average for hospitalizations was up 2% to 27,161, while the daily average for deaths was down 6% to 345. 

    But cases are climbing in some states, raising concerns among health experts. In Nevada, cases are up 92% from two weeks ago, followed by Missouri, where they are up 75%, Tennessee, where they are up 69%, Louisiana, where they are up 68%, and New Mexico, where they have climbed 54%.

    Physicians are reporting high numbers of respiratory illnesses like RSV and the flu earlier than the typical winter peak. WSJ’s Brianna Abbott explains what the early surge means for the coming winter months. Photo illustration: Kaitlyn Wang

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • COVID vaccine maker Moderna
    MRNA,
    -2.21%

    posted far weaker-than-expected third-quarter earnings on Thursday and lowered full-year sales guidance by up to $3 billion. The Cambridge, Mass.-based biotech firm said advance purchase agreements, or APAs, for delivery this year are now expected to total $18 billion to $19 billion of product sales, down from guidance of $21 billion that it provided when it reported second-quarter earnings. The FactSet consensus is for full-year sales of $21.3 billion. For fiscal 2023, Moderna has APAs of $4.5 billion to $5.5 billion. The FactSet consensus for 2023 sales is for $9.4 billion.

    • Virax Biolabs Group Ltd.
    VRAX,
    +36.26%

    stock jumped after the biotechnology company said its triple-virus antigen rapid test kit, which tests for RSV, influenza and COVID, has been launched in the European Union, Dow Jones Newswires reported. The test kit, which can be used in both at-home and point-of-care settings, has also been launched in other markets that accept the CE mark, Virax Biolabs said.

    Testing sewage to track viruses has drawn renewed interest after recent outbreaks of diseases like monkeypox and polio. WSJ visited a wastewater facility to find out how the testing works and what it can tell us about public health. Photo illustration: Ryan Trefes

    • Royal Caribbean Group
    RCL,
    +4.11%

    posted its first quarterly profit since the start of the pandemic, but the cruise-line company said it expected a loss for the current quarter, sending its stock lower on Thursday. Load factors were 96% overall and booking volumes were “significantly higher” than in the same period of prepandemic 2019, as the easing of testing and vaccination protocols provided a boost. For the fourth quarter, the company expects adjusted per-share losses of $1.30 to $1.50, compared with the FactSet loss consensus of 71 cents, and projects revenue of “approximately” $2.6 billion, below the FactSet consensus of $2.7 billion. 

    • The death of a 3-year-old boy in northwestern China following a suspected gas leak at a locked-down residential compound has triggered a fresh wave of outrage at the country’s stringent zero-COVID policy, CNN reported. The boy’s father said in a social media post on Wednesday that COVID workers tried to prevent him from leaving their compound in Lanzhou, the capital of Gansu province, to seek treatment for his child, resulting in what he believes was a fatal delay. The post was met with an outpouring of public anger and grief, with several related hashtags racking up hundreds of millions of views over the following day on Weibo, China’s Twitter-like platform.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 631.4 million on Thursday, while the death toll rose above 6.59 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 97.6 million cases and 1,071,582 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 226.9 million people living in the U.S., equal to 68.4% of the total population, are fully vaccinated, meaning they have had their primary shots.

    So far, just 22.8 million Americans have had the updated COVID booster that targets the original virus and the omicron variants, equal to 7.3% of the overall population.

     

    [ad_2]

    Source link

  • 20 dividend stocks that may be safest if the Federal Reserve causes a recession

    20 dividend stocks that may be safest if the Federal Reserve causes a recession

    [ad_1]

    Investors cheered when a report last week showed the economy expanded in the third quarter after back-to-back contractions.

    But it’s too early to get excited, because the Federal Reserve hasn’t given any sign yet that it is about to stop raising interest rates at the fastest pace in decades.

    Below is a list of dividend stocks that have had low price volatility over the past 12 months, culled from three large exchange traded funds that screen for high yields and quality in different ways.

    In a year when the S&P 500
    SPX,
    -0.40%

    is down 18%, the three ETFs have widely outperformed, with the best of the group falling only 1%.

    Read: GDP looked great for the U.S. economy, but it really wasn’t

    That said, last week was a very good one for U.S. stocks, with the S&P 500 returning 4% and the Dow Jones Industrial Average
    DJIA,
    -0.32%

    having its best October ever.

    This week, investors’ eyes turn back to the Federal Reserve. Following a two-day policy meeting, the Federal Open Market Committee is expected to make its fourth consecutive increase of 0.75% to the federal funds rate on Wednesday.

    The inverted yield curve, with yields on two-year U.S. Treasury notes
    TMUBMUSD02Y,
    4.540%

    exceeding yields on 10-year notes
    TMUBMUSD10Y,
    4.064%
    ,
    indicates investors in the bond market expect a recession. Meanwhile, this has been a difficult earnings season for many companies and analysts have reacted by lowering their earnings estimates.

    The weighted rolling consensus 12-month earning estimate for the S&P 500, based on estimates of analysts polled by FactSet, has declined 2% over the past month to $230.60. In a healthy economy, investors expect this number to rise every quarter, at least slightly.

    Low-volatility stocks are working in 2022

    Take a look at this chart, showing year-to-date total returns for the three ETFs against the S&P 500 through October:


    FactSet

    The three dividend-stock ETFs take different approaches:

    • The $40.6 billion Schwab U.S. Dividend Equity ETF
      SCHD,
      +0.15%

      tracks the Dow Jones U.S. Dividend 100 Indexed quarterly. This approach incorporates 10-year screens for cash flow, debt, return on equity and dividend growth for quality and safety. It excludes real estate investment trusts (REITs). The ETF’s 30-day SEC yield was 3.79% as of Sept. 30.

    • The iShares Select Dividend ETF
      DVY,
      +0.45%

      has $21.7 billion in assets. It tracks the Dow Jones U.S. Select Dividend Index, which is weighted by dividend yield and “skews toward smaller firms paying consistent dividends,” according to FactSet. It holds about 100 stocks, includes REITs and looks back five years for dividend growth and payout ratios. The ETF’s 30-day yield was 4.07% as of Sept. 30.

    • The SPDR Portfolio S&P 500 High Dividend ETF
      SPYD,
      +0.60%

      has $7.8 billion in assets and holds 80 stocks, taking an equal-weighted approach to investing in the top-yielding stocks among the S&P 500. It’s 30-day yield was 4.07% as of Sept. 30.

    All three ETFs have fared well this year relative to the S&P 500. The funds’ beta — a measure of price volatility against that of the S&P 500 (in this case) — have ranged this year from 0.75 to 0.76, according to FactSet. A beta of 1 would indicate volatility matching that of the index, while a beta above 1 would indicate higher volatility.

    Now look at this five-year total return chart showing the three ETFs against the S&P 500 over the past five years:


    FactSet

    The Schwab U.S. Dividend Equity ETF ranks highest for five-year total return with dividends reinvested — it is the only one of the three to beat the index for this period.

    Screening for the least volatile dividend stocks

    Together, the three ETFs hold 194 stocks. Here are the 20 with the lowest 12-month beta. The list is sorted by beta, ascending, and dividend yields range from 2.45% to 8.13%:

    Company

    Ticker

    12-month beta

    Dividend yield

    2022 total return

    Newmont Corp.

    NEM,
    -0.78%
    0.17

    5.20%

    -30%

    Verizon Communications Inc.

    VZ,
    -0.07%
    0.22

    6.98%

    -24%

    General Mills Inc.

    GIS,
    -1.47%
    0.27

    2.65%

    25%

    Kellogg Co.

    K,
    -0.93%
    0.27

    3.07%

    22%

    Merck & Co. Inc.

    MRK,
    -1.73%
    0.29

    2.73%

    35%

    Kraft Heinz Co.

    KHC,
    -0.56%
    0.35

    4.16%

    11%

    City Holding Co.

    CHCO,
    -1.45%
    0.38

    2.58%

    27%

    CVB Financial Corp.

    CVBF,
    -1.24%
    0.38

    2.79%

    37%

    First Horizon Corp.

    FHN,
    -0.18%
    0.39

    2.45%

    53%

    Avista Corp.

    AVA,
    -7.82%
    0.41

    4.29%

    0%

    NorthWestern Corp.

    NWE,
    -0.21%
    0.42

    4.77%

    -4%

    Altria Group Inc

    MO,
    -0.18%
    0.43

    8.13%

    4%

    Northwest Bancshares Inc.

    NWBI,
    +0.10%
    0.45

    5.31%

    11%

    AT&T Inc.

    T,
    +0.63%
    0.47

    6.09%

    5%

    Flowers Foods Inc.

    FLO,
    -0.44%
    0.48

    3.07%

    7%

    Mercury General Corp.

    MCY,
    +0.07%
    0.48

    4.38%

    -43%

    Conagra Brands Inc.

    CAG,
    -0.82%
    0.48

    3.60%

    10%

    Amgen Inc.

    AMGN,
    +0.41%
    0.49

    2.87%

    23%

    Safety Insurance Group Inc.

    SAFT,
    -1.70%
    0.49

    4.14%

    5%

    Tyson Foods Inc. Class A

    TSN,
    -0.40%
    0.50

    2.69%

    -20%

    Source: FactSet

    Any list of stocks will have its dogs, but 16 of these 20 have outperformed the S&P 500 so far in 2022, and 14 have had positive total returns.

    You can click on the tickers for more about each company. Click here for Tomi Kilgore’s detailed guide to the wealth of information available free on the MarketWatch quote page.

    Don’t miss: Municipal bond yields are attractive now — here’s how to figure out if they are right for you

    [ad_2]

    Source link

  • Biden to get updated COVID booster on Tuesday; less than 10% of eligible Americans have had the shot so far

    Biden to get updated COVID booster on Tuesday; less than 10% of eligible Americans have had the shot so far

    [ad_1]

    President Joe Biden will receive his updated COVID booster on Tuesday and will urge Americans to get the shot, which targets both the original virus and omicron variants that have been dominant in the U.S. and elsewhere this year.

    The news, first reported by NBC News, was confirmed by a tweet from White House assistant press secretary Kevin Munoz and by an emailed statement, in which the White House said, “The President will receive his updated COVID-19 vaccine and will deliver remarks on the ongoing fight against the virus.”

    Biden tested positive for COVID-19 in July, then did so again three days after he had been cleared from isolation in a rare rebound case after receiving the anti-viral drug Paxlovid. The president was fully vaccinated and boosted and suffered only mild symptoms. Health officials recommend that people who have contracted COVID wait at least three months after infection to get the booster.

    The bivalent booster has been available to adults and older children since early September, and its use was expanded to children as young as 5 in October. But data from the Centers for Disease Control and Prevention show fewer than 20 million Americans have received it so far — less than 10% of those eligible.

    That’s a slow start given expectations for a wave of new cases in the winter months.

    As immunity from previous shots wanes and new variants spread, health officials are urging people, especially those over 65, to get the updated booster. A study earlier this month by the Commonwealth Fund concluded that a strong booster campaign this fall could save 90,000 American lives and prevent more than 936,000 COVID hospitalizations in the U.S.

    CDC data released Friday showed the two new COVID variants dubbed BQ.1 and BQ.1.1 continued to gain traction in the U.S. in the latest week, accounting for 16.6% of all cases, up from 11.4% a week ago.

    The two variants are lineages of BA.5, the omicron subvariant that remains dominant but has shrunk to account for 62.2% of circulating variants, the agency said, down from 67.9% a week ago. The CDC had previously combined data about BQ.1 and BQ.1.1 with BA.5 cases, because the number of cases caused by the new variants was so small. BQ.1 was first identified by researchers in early September and has been found in the U.K. and Germany, among other places. The New York area, which includes New Jersey, Puerto Rico and the Virgin Islands, has the highest number of cases involving those variants, at 28.4%, the data show.

    U.S. known cases of COVID are continuing to ease and now stand at their lowest level since mid-April, although the true tally is likely higher given how many people overall are testing at home, where data are not being collected.

    The daily average for new cases stood at 37,741 on Sunday, according to a New York Times tracker, down 7% from two weeks ago. The daily average for hospitalizations was down 1% to 26,798, while the daily average for deaths was down 6% to 361.

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • The head of the CDC has tested positive for COVID, the Associated Press reported. Rochelle Walensky, who is up to date on her vaccinations, tested positive Friday night and had mild symptoms, the CDC said in a statement. “Consistent with CDC guidelines, she is isolating at home and will participate in her planned meetings virtually,” the agency said. Senior staff and close contacts have been informed of her positive test and are monitoring their health.

    • The pandemic caused historic learning setbacks for America’s children, erasing decades of academic progress and widening racial disparities, according to results of a national test that provide the sharpest look yet at the scale of the crisis, the AP reported separately. Across the country, math scores saw their largest decreases ever. Reading scores dropped to 1992 levels. Nearly 4 in 10 eighth-graders failed to grasp basic math concepts. Not a single state saw a notable improvement in average test scores, with some treading water at best. Those are the findings from the National Assessment of Educational Progress — known as the “nation’s report card” — which tested hundreds of thousands of fourth- and eighth-graders across the country this year.

    The FDA has authorized modified COVID-19 boosters to target the latest versions of the omicron variant. But as WSJ’s Daniela Hernandez explains, a key part of the decision-making process was changed with these new shots. Photo: Laura Kammermann

    • The Chinese economy grew 3.9% over a year earlier in the third quarter, quickening from the 0.4% expansion recorded in the second quarter, Dow Jones Newswires reported. The reading topped the 3.5% economic growth expected by economists polled by The Wall Street Journal. For the first nine months of the year, China’s GDP expanded 3.0% over a year earlier, well below the 5.5% annual growth target set by the government. Growth has been crimped all year by China’s zero-COVID policy, which has led to repeated lockdowns of commercial and residential areas.

    • The pandemic interrupted measles-vaccine campaigns globally in 2020 and 2021, leaving millions of children unprotected against one of the world’s most contagious diseases, whose complications include blindness, pneumonia and death, Reuters reported. After what health experts call the biggest backslide in a generation, 26 large or disruptive measles outbreaks have occurred worldwide, according to the World Health Organization. A devastating outbreak in Zimbabwe has killed more than 700 children this year, chiefly among religious sects that do not believe in vaccinations.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 627.6 million on Monday, while the death toll rose above 6.57 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 97.2 million cases and 1,067,686 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 226.6 million people living in the U.S., equal to 68.2% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 111.4 million have had a booster, equal to 49.1% of the vaccinated population, and 26.8 million of those who are eligible for a second booster have had one, equal to 40.6% of those who received a first booster.

    [ad_2]

    Source link

  • Pfizer sets new prices for its COVID-19 vaccines. The cost? $110 to $130 per dose

    Pfizer sets new prices for its COVID-19 vaccines. The cost? $110 to $130 per dose

    [ad_1]

    Pfizer Inc.
    PFE,
    +4.17%

    said Thursday that it plans to sell the COVID-19 shot it developed with BioNTech SE
    BNTX,
    +7.14%

    for $110 to $130 per dose once the U.S. market for COVID-19 shots becomes commercial, likely in the first quarter of next year.

    Pfizer and BioNTech are currently paid $30.50 per vaccine dose by the U.S. government, which contracted with the companies (as well as other vaccine makers like Moderna Inc.
    MRNA,
    +6.57%

    and Novavax Inc.
    NVAX,
    +8.88%

    ) and then made the COVID-19 shots available at no cost to people in the U.S. during the public-health emergency.

    The emergency declaration in the U.S. isn’t expected to be renewed next year, which will lead to the formation of an official commercial market for COVID-19 vaccines, tests and treatments. That said, this change doesn’t mean most Americans will be on the hook to pay for their shots in 2023 and beyond.

    A recent Kaiser Family Foundation analysis said most people with private insurance won’t be expected to pay anything out of pocket for the vaccines, though the costs may eventually be baked into the price of health-insurance premiums, as is done with flu shots. People with Medicare will have their shots covered by Medicare Part B, while those with Medicaid should also have coverage of COVID-19 vaccines. It’s the uninsured who may find it difficult to find free vaccines and boosters in the future.

    Wall Street analysts cheered the news, saying Pfizer’s pricing plan came in above expectations. It also bodes well for Moderna’s stock. SVB Securities upgraded the company to market perform from underperform, though the company has not yet announced its pricing plans for its COVID-19 shots.

    “Presuming that MRNA prices as a rational duopolist, this substantially improves the company’s ability to meet 2023 revenue guidance,” SVB analyst Mani Foroohar told investors.

    [ad_2]

    Source link

  • These 27 stocks can give you a more diversified portfolio than the S&P 500 — and that’s a key advantage right now

    These 27 stocks can give you a more diversified portfolio than the S&P 500 — and that’s a key advantage right now

    [ad_1]

    You probably already know that because of market-capitalization weighting, a broad index such as the S&P 500
    SPX,
    -0.67%

    can be concentrated in a handful of stocks. Index funds are popular for good reasons — they tend to have low expenses and it is difficult for active managers to outperform them over the long term.

    For example, look at the SPDR S&P 500 ETF Trust
    SPY,
    -0.71%
    ,
    which tracks the S&P 500 by holding all of its stocks by the same weighting as the index. Five stocks — Apple Inc.
    AAPL,
    +0.08%
    ,
    Microsoft Corp.
    MSFT,
    -0.85%
    ,
    Amazon.com Inc.
    AMZN,
    -1.11%
    ,
    Alphabet Inc.
    GOOG,
    -1.08%

    GOOGL,
    -1.13%

    and Tesla Inc.
    TSLA,
    +0.84%
    ,
    make up 21.5% of the portfolio.

    But there are other considerations when it comes to diversification — namely, factors. During an interview, Scott Weber of Vaughan Nelson Investment Management in Houston explained how groups of stock and commodities can move together, adding to a lack of diversification in a typical portfolio or index fund.

    Weber co-manages the $293 million Natixis Vaughan Nelson Select Fund
    VNSAX,
    -0.96%
    ,
    which carries a five-star rating (the highest) from investment-researcher Morningstar, and has outperformed its benchmark, the S&P 500.

    Vaughan Nelson is a Houston-based affiliate of Natixis Investment Managers, with about $13 billion in assets under management, including $5 billion managed under the same strategy as the fund, including the Natixis Vaughan Nelson Select ETF
    VNSE,
    -0.87%
    .
    The ETF was established in Sept, 2020, so does not yet have a Morningstar rating.

    Factoring-in the factors

    Weber explained how he and colleagues incorporate 35 factors into their portfolio selection process. For example, a fund might hold shares of real-estate investment trusts (REITs), financial companies and energy producers. These companies are in different sectors, as defined by Standard & Poor’s. Yet their performance may be correlated.

    Weber pointed out that REITs, for example, were broken out of the financial sector to become their own sector in 2016. “Did that make REIT’s more sensitive to interest rates? The answer is no,” he said. “The S&P sector buckets are somewhat  better than arbitrary, but they are not perfect.”

    Of course 2022 is something of an exception, with so many assets dropping in price at the same time. But over the long term, factor analysis can identify correlations and lead money managers to limit their investments in companies, sectors or industries whose prices tend to move together. This style has helped the Natixis Vaughan Nelson Select Fund outperform against its benchmark, Weber said.

    Getting back to the five largest components of the S&P 500, they are all tech-oriented, even though only two, Apple and Microsoft, are in the information technology sector, while Alphabet is in the communications sector and Tesla is in the consumer discretionary sector. “Regardless of the sectors,” they tend to move together, Weber said.

    Exposure to commodity prices, timing of revenue streams through economic cycles (which also incorporates currency exposure), inflation and many other items are additional factors that Weber and his colleagues incorporate into their broad allocation strategy and individual stock selections.

    For example, you might ordinarily expect inflation, real estate and gold to move together, Weber said. But as we are seeing this year, with high inflation and rising interest rates, there is downward pressure on real-estate prices, while gold prices
    GC00,
    -0.01%

    have declined 10% this year.

    Digging further, the factors also encompass sensitivity of investments to U.S. and other countries’ government bonds of various maturities, credit spreads between corporate and government bonds in developed countries, exchange rates, and measures of liquidity, price volatility and momentum.

    Stock selection

    The largest holding of the Select fund is NextEra Energy Inc.
    NEE,
    -1.89%
    ,
    which owns FPL, Florida’s largest electric utility. FPL is phasing-out coal plants and replacing power-generating capacity with natural gas as well as wind and solar facilities.

    Weber said: “There’s not a company on the planet that is better at getting alternate (meaning solar and wind) generation deployed. But because they own FPL, some of my investors say it is one of the largest carbon emitters on the planet.”

    He added that “as a consequence of their skill in operating, they re generating amazing returns for investors.” NextEra’s share shave returned 446% over the past 10 years. One practice that has helped to elevate the company’s return on equity, and presumably its stock price, has been “dropping assets down” into NextEra Energy Partners LP
    NEP,
    -2.61%
    ,
    which NEE manages, Weber said. He added that the assets put into the partnership tend to be “great at cash-flow generation, but not on achieving growth.”

    When asked for more examples of stocks in the fund that may provide excellent long-term returns, Weber mentioned Monolithic Power Systems Inc.
    MPWR,
    -0.24%
    ,
    as a way to take advantage of the broad decline in semiconductor stocks this year. (The iShares Semiconductor ETF
    SOXX,
    +0.64%

    has declined 21% this year, while industry stalwarts Nvidia Corp.
    NVDA,
    +0.70%

    and Advanced Micro Devices Inc.
    AMD,
    -1.19%

    are down 59% and 60%, respectively.)

    He said Monolithic Power has been consistently making investments that improve its return on invested capital (ROIC). A company’s ROIC is its profit divided by the sum of the carrying value of stock it has issued over the years and its current debt. It doesn’t reflect the stock price and is considered a good measure of a management team’s success at making investment decisions and managing projects. Monolithic Power’s ROICC for 2021 was 21.8%, according to FactSet, rising from 13.2% five years earlier.

    “We want to see a business generating a return on capital in excess of its cost of capital. In addition, they need to invest their capital at incrementally improving returns,” Weber said.

    Another example Weber gave of a stock held by the fund is Dollar General Corp.
    DG,
    +0.33%
    ,
    which he called a much better operator than rival Dollar Tree Inc.
    DLTR,
    +0.14%
    ,
    which owns Family Dollar. He cited DG’s roll-out of frozen-food and fresh food offerings, as well as its growth runway: “They still have 8,000 or 9,000 stores to build-out” in the U.S., he said.

    Fund holdings

    In order to provide a full current list of stocks held under Weber’s strategy, here are the 27 stocks held by the the Natixis Vaughan Select ETF as of Sept. 30. The largest 10 positions made up 49% of the portfolio:

    Company

    Ticker

    % of portfolio

    NextEra Energy Inc.

    NEE,
    -1.89%
    5.74%

    Dollar General Corp.

    DG,
    +0.33%
    5.51%

    Danaher Corp.

    DHR,
    -2.89%
    4.93%

    Microsoft Corp.

    MSFT,
    -0.85%
    4.91%

    Amazon.com Inc.

    AMZN,
    -1.11%
    4.90%

    Sherwin-Williams Co.

    SHW,
    -2.53%
    4.80%

    Wheaton Precious Metals Corp.

    WPM,
    -2.28%
    4.76%

    Intercontinental Exchange Inc.

    ICE,
    -1.16%
    4.52%

    McCormick & Co.

    MKC,
    +0.11%
    4.48%

    Clorox Co.

    CLX,
    +1.27%
    4.39%

    Aon PLC Class A

    AON,
    +0.21%
    4.33%

    Jack Henry & Associates Inc.

    JKHY,
    -0.97%
    4.08%

    Motorola Solutions Inc.

    MSI,
    -0.64%
    4.08%

    Vertex Pharmaceuticals Inc.

    VRTX,
    -2.72%
    4.01%

    Union Pacific Corp.

    UNP,
    -0.78%
    3.99%

    Alphabet Inc. Class A

    GOOGL,
    -1.13%
    3.03%

    Johnson & Johnson

    JNJ,
    -0.80%
    2.98%

    Nvidia Corp.

    NVDA,
    +0.70%
    2.92%

    Cogent Communications Holdings Inc.

    CCOI,
    -2.10%
    2.81%

    Kosmos Energy Ltd.

    KOS,
    +5.62%
    2.68%

    VeriSign Inc.

    VRSN,
    -0.43%
    2.15%

    Chemed Corp.

    CHE,
    -0.73%
    2.06%

    Berkshire Hathaway Inc. Class B

    BRK.B,
    -1.18%
    2.00%

    Saia Inc.

    SAIA,
    -4.36%
    1.97%

    Monolithic Power Systems Inc.

    MPWR,
    -0.24%
    1.96%

    Entegris Inc.

    ENTG,
    -0.17%
    1.93%

    Luminar Technologies Inc. Class A

    LAZR,
    -6.90%
    0.96%

    Source: Natixis Funds

    You can click on the tickers for more about each company. Click here for a detailed guide to the wealth of information available free on the MarketWatch.com quote page.

    Fund performance

    The Natixis Vaughan Select Fund was established on June 29, 2012. Here’s a 10-year chart showing the total return of the fund’s Class A shares against that of the S&P 500, with dividends reinvested. Sales charges are excluded from the chart and the performance numbers. In the current environment for mutual-fund distribution, sales charges are often waived for purchases of new shares through investment advisers.


    FactSet

    Here’s a comparison of returns for 2022 and average annual returns for various periods of the fund’s Class A shares to that of the S&P 500 and its Morningstar fund category through Oct. 18:

     

    Total return – 2022 through Oct. 18

    Average return – 3 Years

    Average return – 5 Years

    Average return – 10 years

    Vaughan Nelson Select Find – Class A

    -20.2%

    11.8%

    10.8%

    13.0%

    S&P 500

    -21.0%

    9.4%

    9.7%

    12.0%

    Morningstar Large Blend category

    -20.3%

    8.1%

    8.2%

    10.7%

    Sources: Morningstar, FactSet

    [ad_2]

    Source link

  • Moderna Stock Takes Off on Cancer Vaccine News

    Moderna Stock Takes Off on Cancer Vaccine News

    [ad_1]



    Moderna


    stock shot up after


    Merck


    said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker.

    Merck (ticker: MRK) will pay


    Moderna


    (MRNA) $250 million for the joint development and future commercialization of the vaccine, which is currently in Phase 2 clinical trials. The two companies had announced a “strategic collaboration” in June 2016.

    [ad_2]

    Source link

  • Philips warns of 5% fall in like-for-like sales due to supply-chain woes

    Philips warns of 5% fall in like-for-like sales due to supply-chain woes

    [ad_1]

    Royal Philips NV said Wednesday that its performance for the third quarter was hurt by stronger-than-anticipated supply-chain challenges, and adopted a more pessimistic view on its sales through the end of the year.

    The Dutch health-technology company
    PHIA,
    -8.01%

    PHG,
    -0.80%

    said that it expects to record a 1.3 billion euro ($1.26 billion) impairment charge in the period. The company said that this is an impairment of goodwill of Philips Respironics, its sleep and respiratory care business, and that it is due to revisions to the business’s financial forecast.

    This compares with adjusted Ebita of EUR512 million, or 12.3% of sales, a year earlier.

    Analysts had seen the metric at EUR336 million, according to a consensus estimate provided by the company.

    Philips expects to book a EUR1.3 billion impairment charge on its sleep and respiratory care business after revising its financial forecast for the unit, it said.

    Group comparable sales for the quarter fell around 5%.

    For the last quarter of the year, Philips now expects a mid-single-digit decline in comparable sales, it said.

    In late July, Philips had guided for 6%-9% growth in comparable sales over the second half of the year.

    “Philips still expects a better second half of the year, compared to the first half of 2022. However, the company sees prolonged supply chain disruptions and a worsening macro-environment,” it said.

    The company said it expects adjusted Ebita margin to be in the range of a high single to double digit for the last quarter of the year.

    Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com and Cristina Roca at cristina.roca@wsj.com

    [ad_2]

    Source link

  • WSJ News Exclusive | Bio-Rad Laboratories in Talks to Combine With Qiagen

    WSJ News Exclusive | Bio-Rad Laboratories in Talks to Combine With Qiagen

    [ad_1]

    Bio-Rad Laboratories is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

    The talks have been going on for a while but any agreement isn’t likely for another few weeks or more—and there may not be one.

    [ad_2]

    Source link

  • 21 dividend stocks yielding 5% or more of companies that will produce plenty of cash in 2023

    21 dividend stocks yielding 5% or more of companies that will produce plenty of cash in 2023

    [ad_1]

    When the stock market has jumped two days in a row, as it has now, it is easy to become complacent.

    But the Federal Reserve isn’t finished raising interest rates, and recession talk abounds. Stock investors aren’t out of the woods yet. That can make dividend stocks attractive if the yields are high and the companies produce more cash flow than they need to cover the payouts.

    Below is a list of 21 stocks drawn from the S&P Composite 1500 Index
    SP1500,
    +3.12%

    that appear to fit the bill. The S&P Composite 1500 is made up of the S&P 500
    SPX,
    +3.06%
    ,
    the S&P 400 Mid Cap Index
    MID,
    +3.18%

    and the S&P Small Cap 600 Index
    SML,
    +3.80%
    .

    The purpose of the list is to provide a starting point for further research. These stocks may be appropriate for you if you are looking for income, but you should do your own assessment to form your own opinion about a company’s ability to remain competitive over the next decade.

    Cash flow is key

    One way to measure a company’s ability to pay dividends is to look at its free cash flow yield. Free cash flow is remaining cash flow after planned capital expenditures. This money can be used to pay for dividends, buy back shares (which can raise earnings and cash flow per share), or fund acquisitions, organic expansion or for other corporate purposes.

    If we divide a company’s estimated annual free cash flow per share by its current share price, we have its estimated free cash flow yield. If we compare the free cash flow yield to the current dividend yield, we may see “headroom” for cash to be deployed in ways that can benefit shareholders.

    For this screen, we began with the S&P Composite 1500, then narrowed the list as follows:

    • Dividend yield of at least 5.00%.

    • Consensus free cash flow estimate available for calendar 2023, among at least five analysts polled by FactSet. We used calendar-year estimates, even though fiscal years for many companies don’t match the calendar.

    • Estimated 2023 free cash flow yield of at least double the current dividend yield.

    For real-estate investment trusts, dividend-paying ability is measured by funds from operations (FFO), a non-GAAP figure that adds depreciation and amortization back to earnings. Adjusted funds from operations (AFFO) takes this a step further, subtracting cash expected to be used to maintain properties. So for the two REITs on the list, the FCF yield column makes use of AFFO.

    For many companies in the financial sector, especially banks and insurers, free cash flow figures aren’t available, so the screen made use of earnings-per-share estimates. These are generally considered to run close to actual cash flow for these heavily regulated industries.

    Here are the 21 companies that passed the screen, with dividend yields of at least 5% and estimated 2023 FCF yields at least twice the current payout. They are sorted by dividend yield:

    Company

    Ticker

    Type

    Dividend yield

    Estimated 2023 FCF yield

    Estimated “headroom”

    Uniti Group Inc.

    UNIT,
    +7.36%
    Real-Estate Investment Trusts

    8.33%

    25.25%

    16.92%

    Hanesbrands Inc.

    HBI,
    +5.56%
    Apparel/ Footwear

    8.33%

    17.29%

    8.96%

    Kohl’s Corp.

    KSS,
    +5.80%
    Department Stores

    7.68%

    16.72%

    9.04%

    Rent-A-Center Inc.

    RCII,
    +10.40%
    Finance/ Rental/ Leasing

    7.52%

    17.26%

    9.73%

    Macerich Co.

    MAC,
    +8.18%
    Real-Estate Investment Trusts

    7.43%

    18.04%

    10.60%

    Devon Energy Corp.

    DVN,
    +5.72%
    Oil & Gas Production

    7.13%

    14.47%

    7.33%

    AT&T Inc.

    T,
    +1.19%
    Major Telecommunications

    6.98%

    14.82%

    7.84%

    Newell Brands Inc.

    NWL,
    +5.16%
    Industrial Conglomerates

    6.59%

    17.42%

    10.82%

    Dow Inc.

    DOW,
    +2.96%
    Chemicals

    6.18%

    15.63%

    9.45%

    LyondellBasell Industries NV

    LYB,
    +3.64%
    Chemicals

    6.09%

    16.07%

    9.99%

    Scotts Miracle-Gro Co. Class A

    SMG,
    +5.01%
    Chemicals

    6.04%

    12.68%

    6.65%

    Diamondback Energy Inc.

    FANG,
    +5.23%
    Oil & Gas Production

    5.56%

    13.63%

    8.08%

    Best Buy Co. Inc.

    BBY,
    +5.86%
    Electronics/ Appliance Stores

    5.53%

    14.08%

    8.55%

    Viatris Inc.

    VTRS,
    +5.62%
    Pharmaceuticals

    5.50%

    28.95%

    23.45%

    Prudential Financial Inc.

    PRU,
    +5.66%
    Life/ Health Insurance

    5.38%

    13.30%

    7.91%

    Ford Motor Co.

    F,
    +7.76%
    Motor Vehicles

    5.23%

    15.95%

    10.72%

    Invesco Ltd.

    IVZ,
    +6.76%
    Investment Managers

    5.23%

    14.95%

    9.73%

    Franklin Resources Inc.

    BEN,
    +4.37%
    Investment Managers

    5.17%

    13.21%

    8.04%

    Kontoor Brands Inc.

    KTB,
    +0.73%
    Apparel/ Footwear

    5.17%

    14.15%

    8.98%

    Seagate Technology Holdings PLC

    STX,
    +4.09%
    Computer Peripherals

    5.11%

    13.19%

    8.07%

    Foot Locker Inc.

    FL,
    +1.35%
    Apparel/ Footwear Retail

    5.03%

    15.52%

    10.49%

    Source: FactSet

    Any stock screen has its limitations. If you are interested in stocks listed here, it is best to do your own research, and it is easy to get started by clicking the tickers in the table for more information about each company. Click here for Tomi Kilgore’s detailed guide to the wealth of information for free on the MarketWatch quote page.

    For the “estimated FCF yields,” consensus free cash flow estimates for calendar 2023 were used for all companies except the following:

    Don’t miss: Dividend yields on preferred stocks have soared. This is how to pick the best ones for your portfolio.

    [ad_2]

    Source link